Trial Profile
Effect of bevacizumab in combinations of EGFR tyrosine kinase inhibitor (TKI) in patients with EGFR mutated lung adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 02 May 2018 New trial record
- 20 Apr 2018 Results published in the Journal of Thoracic Oncology